Γ

SynBioBeta Speaker

Mark Atalla

ONC

ONC Deputy, Policy

Dr. Mark Atalla serves as the Deputy National Coordinator for Health IT, Policy at the Office of the National Coordinator for Health IT (ONC) in the Department of Health and Human Services (HHS). He leads efforts to advance technology-driven health policy, focusing on ways digital tools and intelligent systems can enhance behavior change, lower healthcare spending, and strengthen delegated financial risk models.Dr. Atalla brings extensive experience from a large, distributed healthcare organization with more than 2,000 clinics nationwide, as well as leadership roles across pharmacy benefit management, community pharmacy, and hospital pharmacy operations.Prior to his current role, Dr. Atalla served as a Senior Advisor at the Centers for Medicare & Medicaid Services (CMS) for Innovation, where he led key Medicare Advantage and Part D initiatives at the CMS Innovation Center—including the Part D Senior Savings Model, Part D Payment Modernization Model, and Medicare Advantage Value-Based Insurance Design (VBID) Model.Dr. Atalla has also held operational roles at Medco/Express Scripts and Fresenius. He holds a Doctor of Pharmacy (PharmD) degree from the University of Florida and an MBA from Yale University.

Sessions Featuring

Mark

This Year

Breakout Session

4:30 PM

-

5:15 PM

Human Health

Rewriting the Rules - Clinical Trial Reform in the Age of AI

AI-native drug discovery is accelerating molecule design, but clinical trials remain slow, expensive, and exclusionary. If we don’t modernize trial infrastructure, we create a bottleneck between computational breakthroughs and real-world patient impact.  This breakout explores how to reform recruitment, eligibility, endpoints, biomarkers, and regulatory alignment to make U.S. trials more competitive and globally scalable.

Breakout Session

4:30 PM

-

5:15 PM

Human Health

Rewriting the Rules - Clinical Trial Reform in the Age of AI

AI-native drug discovery is accelerating molecule design, but clinical trials remain slow, expensive, and exclusionary. If we don’t modernize trial infrastructure, we create a bottleneck between computational breakthroughs and real-world patient impact.  This breakout explores how to reform recruitment, eligibility, endpoints, biomarkers, and regulatory alignment to make U.S. trials more competitive and globally scalable.

TBD

Session lineup still growing

Featuring

Speaker Coming Soon

Fireside Chat

12:00 AM

-

8:30 AM

Human Health

From Cells to Patients: Solving the Scale Mismatch in Virtual Biology

Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?

Featuring

Speaker Coming Soon

Previous Speakers Include